Sign In
Buy ALPMY
$13.40
-0.200 (-1.47%)
At Close: Jun 03, 2026
- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 - - XNW27011 has demonstrated encouraging
Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers
10:00am, Wednesday, 28'th May 2025
Building on a successful inaugural year, the initiative sponsored by Astellas' Patient Centricity team continues to connect individuals with vital resources and support from patient advocacy organizat
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
10:45am, Tuesday, 27'th May 2025
Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.
Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio
11:00am, Wednesday, 21'st May 2025
Both companies have earned a year-long opportunity for access to a distinguished life-science incubator in San Francisco along with the invaluable expertise provided by Astellas to advance their resea
Here's Why Astellas Pharma (ALPMY) Is a Great 'Buy the Bottom' Stock Now
10:55am, Tuesday, 13'th May 2025
Astellas Pharma (ALPMY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could m
Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses
09:00am, Thursday, 01'st May 2025
ARVO and RWC abstracts feature analyses on biomarkers, mechanism of disease, patient experience and other data from IZERVAY ™ (avacincaptad pegol intravitreal solution) pivotal studies TOKYO , M
Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:06pm, Tuesday, 29'th Apr 2025
Astellas Pharma (ALPMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
10:46am, Monday, 28'th Apr 2025
Here is how Astellas Pharma Inc. (ALPMY) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript
06:02pm, Saturday, 26'th Apr 2025
Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2024 Earnings Conference Call April 25, 2025 4:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Naoki Okamura - Representative
Singlera Genomics Presented Non-Invasive Testicular Toxicity Detection with Astellas at 2025 SOT Meeting
11:48am, Monday, 24'th Mar 2025
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Singlera Genomics presented results showing a refined approach to detect drug-induced testicular toxicity using Singlera's cell-free DNA methylation techn
Astellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline Forward
09:56am, Saturday, 15'th Mar 2025
Astellas Pharma Inc. has a diverse pipeline with significant growth in oncology, driven by new approvals for drugs like zolbetuximab. Despite recent stock declines, ALPMF's revenue and core profits ha
Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize
10:00am, Thursday, 27'th Feb 2025
Awardees win a year of access to a prestigious life-science incubator in San Francisco and to Astellas expertise to further their research Award helps biotech start-ups accelerate early drug discover
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
10:04am, Thursday, 13'th Feb 2025
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI®
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
06:32pm, Wednesday, 12'th Feb 2025
IZERVAY dosing approved beyond 12 months TOKYO , Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug A
Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript
01:51pm, Saturday, 08'th Feb 2025
Astellas Pharma Inc. (OTCPK:ALPMF) Q3 2024 Earnings Conference Call February 4, 2025 2:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Atsushi Kitamura - Chief Fina
